David Baker
Co-Founder
Cyrus Biotechnology
4/10Traction
Cyrus Biotechnology utilizes AI-driven protein design and deep mutagenesis to develop biologics targeting severe autoimmune diseases and COVID-19. Their platform has advanced over 30 discovery programs, focusing on IgG-driven conditions and engineered therapeutics that enhance efficacy and safety for patients.
- Artificial Intelligence
- Biotechnology
Updated 6 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Developing effective biologics for severe autoimmune diseases and viral infections is challenging due to the complexity of protein structures and the need for enhanced efficacy and safety profiles. Traditional methods of protein engineering are often slow, costly, and may not fully optimize therapeutic potential.
Solution
Cyrus Biotechnology leverages an AI-driven protein design platform combined with deep mutagenesis techniques to create novel biologics. The platform focuses on engineering naturally existing proteins into superior therapeutics for autoimmune conditions and viral infections. By integrating advanced algorithms and sophisticated laboratory methods, Cyrus Biotechnology aims to accelerate the discovery process and improve the therapeutic properties of its biologic candidates, including enhanced target specificity and reduced off-target effects. The company's lead programs target IgG-driven autoimmune diseases and develop immunomodulatory cytokines with improved efficacy.
Target Audience
The primary target audience includes patients suffering from severe autoimmune diseases such as gMG and ITP, individuals at risk of COVID-19 infection, and pharmaceutical companies seeking novel biologic candidates for licensing or co-development.
Features
- AI-driven protein design platform utilizing novel algorithms to optimize protein structure and function.
- Deep mutagenesis technology to generate and screen a wide range of protein variants.
- Focus on engineering naturally existing proteins for improved therapeutic potential.
- Development of IdeS, an IgG-depleting enzyme, for the treatment of IgG-driven autoimmune diseases.
- Development of IL-22 fusion proteins with enhanced efficacy for autoimmune gastrointestinal and metabolic indications.
- Development of sACE2.v2-Fc, a COVID-19 candidate designed to be effective against all variants.